Hong Kong start-up FuSure Re eyes China health market
June 2 2021 by Andrew Tjaardstra
-
Fidelidade Macau improves ROE on China border reopening, light rail transit project: Fitch
- November 22
The rating agency has affirmed the P&C carri rating at 'A' (strong) with a stable outlook driven by the insurer's strategic importance to its Portuguese parent company.
-
Seoul Guarantee Insurance could see decline in underwriting performance on a rise in paid claims: Fitch
- November 21
The rating agency has affirmed SGI’s rating at 'AA-' (very strong) with a stable outlook taking into account its strong capitalisation, financial performance, and the support it receives from the government.
-
Tugu Re’s property, credit businesses adds volatility as 2023 COR rises to 107%: Fitch
- November 18
The global rating agency has affirmed Tugure’s rating at 'A+(idn)' with a stable outlook.
-
China Re’s overseas P&C business posts robust growth, says AM Best affirming its rating
- November 18
The rating agency noted Chaucer continues to be the major driver of overseas non-life reinsurance revenue.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
